Citadel Advisors
BHVN

Citadel Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Citadel Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,300
Closed -$1.25M – 16124
2022
Q3 		$1.25M Sell
8,300
-15,300
-65% -$2.27M ﹤0.01% 6506
2022
Q2 		$3.44M Sell
23,600
-21,300
-47% -$2.72M ﹤0.01% 4511
2022
Q1 		$5.32M Sell
44,900
-26,900
-37% -$3.36M ﹤0.01% 4052
2021
Q4 		$9.89M Sell
71,800
-11,200
-13% -$1.42M ﹤0.01% 3094
2021
Q3 		$11.5M Buy
83,000
+36,900
+80% +$4.61M ﹤0.01% 2823
2021
Q2 		$4.47M Sell
46,100
-34,700
-43% -$2.82M ﹤0.01% 4675
2021
Q1 		$5.52M Sell
80,800
-91,100
-53% -$7.37M ﹤0.01% 4038
2020
Q4 		$14.7M Buy
171,900
+93,200
+118% +$7.9M ﹤0.01% 2150
2020
Q3 		$5.12M Sell
78,700
-75,700
-49% -$4.96M ﹤0.01% 3124
2020
Q2 		$11.3M Buy
154,400
+38,200
+33% +$2.03M ﹤0.01% 2084
2020
Q1 		$3.95M Sell
116,200
-356,600
-75% -$16.3M ﹤0.01% 3055
2019
Q4 		$25.7M Buy
472,800
+4,900
+1% +$243K 0.01% 1260
2019
Q3 		$19.5M Buy
467,900
+9,000
+2% +$380K 0.01% 1496
2019
Q2 		$20.1M Buy
458,900
+388,500
+552% +$21.9M 0.01% 1426
2019
Q1 		$3.62M Buy
70,400
+57,800
+459% +$2.5M ﹤0.01% 3457
2018
Q4 		$466K Buy
+12,600
New +$454K ﹤0.01% 6513
2018
Q3 		– Sell
-13,100
Closed -$518K – 10184
2018
Q2 		$518K Sell
13,100
-419,300
-97% -$13.3M ﹤0.01% 6305
2018
Q1 		$11.1M Buy
432,400
+415,200
+2,414% +$12.4M 0.01% 1614
2017
Q4 		$464K Buy
+17,200
New +$474K ﹤0.01% 5770

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Citadel Advisors's BHVN Position: Q4 2022 in Review

Citadel Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 185,618 shares — an estimated $28.1M sold.

Citadel Advisors first reported a position in BHVN in Q3 2017 and held it in 21 quarters. The position peaked at $56.6M in Q2 2019. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Citadel Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 185,618 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $28.1M.
  • Citadel Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2017 and held it in 21 quarters.
  • Citadel Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $56.6M in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.